Clinical Trials Logo

Filter by:
NCT ID: NCT01136174 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Start date: May 2010
Phase: Phase 2
Study type: Interventional

To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment. To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone background treatment. To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with BIBF 1120 treatment.

NCT ID: NCT01135927 Completed - Diabetes Clinical Trials

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 (insulin degludec) in Japanese subjects with type 1 diabetes.

NCT ID: NCT01135511 Completed - Dry Eye Syndromes Clinical Trials

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

NCT ID: NCT01135433 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients

Start date: May 15, 2010
Phase: Phase 3
Study type: Interventional

This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and metformin in patients with diabetes mellitus.

NCT ID: NCT01134055 Completed - Clinical trials for Macular Degeneration

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Start date: June 1, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

NCT ID: NCT01134042 Completed - Asthma Clinical Trials

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.

NCT ID: NCT01132625 Completed - Clinical trials for Advanced Solid Tumors

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Start date: November 2008
Phase: Phase 1
Study type: Interventional

This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.

NCT ID: NCT01132612 Completed - Clinical trials for Plaque-type Psoriasis

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Start date: May 11, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

NCT ID: NCT01131676 Completed - Clinical trials for Diabetes Mellitus, Type 2

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.

NCT ID: NCT01129674 Terminated - Schizophrenia Clinical Trials

A Long-Term, Open-Label, Study on Schizophrenia

Start date: June 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.